(LENZ) LENZ Therapeutics - Ratings and Ratios
Presbyopia, Accommodative, Therapeutics
Description: LENZ LENZ Therapeutics
LENZ Therapeutics Inc, a biotechnology company listed on NASDAQ under the ticker symbol LENZ, operates in the United States. The companys stock is classified as common stock within the biotechnology sub-industry according to the GICS classification.
The quarterly tax provision data suggests that the company is navigating complex financial and operational challenges, potentially related to its research and development activities, a common characteristic of biotech firms. Biotech companies often report significant losses due to high R&D expenses, which can lead to negative earnings and, consequently, a P/E ratio of 0.00, as seen in LENZs financials.
With a market capitalization of $1036.21M USD, LENZ Therapeutics has a considerable presence in the market. The absence of a Beta value indicates that the companys stock volatility relative to the overall market is not readily available or calculable, possibly due to the stocks relatively short trading history or insufficient data. The negative Return on Equity (RoE) of -25.63% highlights the companys current unprofitability, a common trait among biotech firms that are investing heavily in drug development.
Key economic drivers for LENZ include the success of its drug pipeline, regulatory approvals, and the ability to bring new therapies to market. Critical KPIs to watch would include the progress of clinical trials, the companys cash burn rate, and the estimated time to profitability. The stocks price action, with a current price of $39.68 and a 52-week range of $18.32 to $40.91, indicates significant volatility and potential investor interest in the companys prospects.
The average trading volume of 611,142 shares suggests a relatively liquid stock, which is important for investors looking to enter or exit positions without significantly impacting the stock price. The short-term and long-term moving averages (SMA20, SMA50, SMA200) indicate a positive trend, with the stock price above these averages, suggesting a potential uptrend.
LENZ Stock Overview
| Market Cap in USD | 1,164m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-06-25 |
LENZ Stock Ratings
| Growth Rating | 51.6% |
| Fundamental | 33.9% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | 68.9% |
| Analyst Rating | 4.63 of 5 |
LENZ Dividends
Currently no dividends paidLENZ Growth Ratios
| Growth Correlation 3m | 83.2% |
| Growth Correlation 12m | 47.7% |
| Growth Correlation 5y | -18.7% |
| CAGR 5y | 26.98% |
| CAGR/Max DD 3y | 0.53 |
| CAGR/Mean DD 3y | 1.17 |
| Sharpe Ratio 12m | 1.37 |
| Alpha | 0.24 |
| Beta | 0.535 |
| Volatility | 64.46% |
| Current Volume | 372.6k |
| Average Volume 20d | 402.2k |
| Stop Loss | 39.7 (-6%) |
| Signal | 1.11 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-52.4m TTM) > 0 and > 6% of Revenue (6% = 304.0k TTM) |
| FCFTA -0.28 (>2.0%) and ΔFCFTA 2.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.22 (>3.0%) and CFO -47.2m > Net Income -52.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 20.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (28.1m) change vs 12m ago 9.65% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 2.41% (prev 0.0%; Δ 2.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -15.17
| (A) 0.93 = (Total Current Assets 213.6m - Total Current Liabilities 10.4m) / Total Assets 217.3m |
| (B) -0.80 = Retained Earnings (Balance) -174.5m / Total Assets 217.3m |
| (C) -0.30 = EBIT TTM -62.0m / Avg Total Assets 210.0m |
| (D) -15.91 = Book Value of Equity -174.5m / Total Liabilities 11.0m |
| Total Rating: -15.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.90
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -6.26% = -3.13 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -0.02 = -2.50 |
| 6. ROIC - WACC (= -38.29)% = -12.50 |
| 7. RoE -25.63% = -2.50 |
| 8. Rev. Trend 49.02% = 3.68 |
| 9. EPS Trend 67.13% = 3.36 |
What is the price of LENZ shares?
Over the past week, the price has changed by +1.25%, over one month by +8.92%, over three months by +45.82% and over the past year by +100.14%.
Is LENZ Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LENZ is around 38.58 USD . This means that LENZ is currently overvalued and has a potential downside of -8.64%.
Is LENZ a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LENZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50.9 | 20.5% |
| Analysts Target Price | 50.9 | 20.5% |
| ValueRay Target Price | 42.8 | 1.4% |
Last update: 2025-09-13 04:37
LENZ Fundamental Data Overview
CCE Cash And Equivalents = 209.5m USD (Cash And Short Term Investments, last quarter)
P/S = 232.7974
P/B = 5.6404
Beta = None
Revenue TTM = 5.07m USD
EBIT TTM = -62.0m USD
EBITDA TTM = -61.9m USD
Long Term Debt = 569.0k USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 482.0k USD (from shortTermDebt, last quarter)
Debt = 1.05m USD (Calculated: Short Term 482.0k + Long Term 569.0k)
Net Debt = -36.6m USD (from netDebt column, last quarter)
Enterprise Value = 955.5m USD (1.16b + Debt 1.05m - CCE 209.5m)
Interest Coverage Ratio = unknown (Ebit TTM -62.0m / Interest Expense TTM 0.0)
FCF Yield = -6.26% (FCF TTM -59.9m / Enterprise Value 955.5m)
FCF Margin = -1182 % (FCF TTM -59.9m / Revenue TTM 5.07m)
Net Margin = -1034 % (Net Income TTM -52.4m / Revenue TTM 5.07m)
Gross Margin = 98.44% ((Revenue TTM 5.07m - Cost of Revenue TTM 79.0k) / Revenue TTM)
Tobins Q-Ratio = -5.48 (set to none) (Enterprise Value 955.5m / Book Value Of Equity -174.5m)
Interest Expense / Debt = 1.90% (Interest Expense 20.0k / Debt 1.05m)
Taxrate = 21.0% (US default)
NOPAT = -62.0m (EBIT -62.0m, no tax applied on loss)
Current Ratio = 20.54 (Total Current Assets 213.6m / Total Current Liabilities 10.4m)
Debt / Equity = 0.01 (Debt 1.05m / last Quarter total Stockholder Equity 206.4m)
Debt / EBITDA = -0.02 (Net Debt -36.6m / EBITDA -61.9m)
Debt / FCF = -0.02 (Debt 1.05m / FCF TTM -59.9m)
Total Stockholder Equity = 204.4m (last 4 quarters mean)
RoA = -24.11% (Net Income -52.4m, Total Assets 217.3m )
RoE = -25.63% (Net Income TTM -52.4m / Total Stockholder Equity 204.4m)
RoCE = -30.22% (Ebit -62.0m / (Equity 204.4m + L.T.Debt 569.0k))
RoIC = -30.31% (NOPAT -62.0m / Invested Capital 204.4m)
WACC = 7.98% (E(1.16b)/V(1.17b) * Re(7.99%)) + (D(1.05m)/V(1.17b) * Rd(1.90%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 81.82 | Cagr: 12.24%
Discount Rate = 7.99% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -59.9m)
EPS Correlation: 67.13 | EPS CAGR: 21.53% | SUE: 0.04 | # QB: 0
Revenue Correlation: 49.02 | Revenue CAGR: 139.2% | SUE: N/A | # QB: None
Additional Sources for LENZ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle